Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,000 shares of the company’s stock, valued at approximately $830,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Usca Ria LLC acquired a new stake in shares of LivaNova in the third quarter valued at $75,000. US Bancorp DE raised its stake in shares of LivaNova by 11.5% in the second quarter. US Bancorp DE now owns 1,452 shares of the company’s stock valued at $104,000 after acquiring an additional 150 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of LivaNova by 585.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,501 shares of the company’s stock valued at $108,000 after acquiring an additional 1,282 shares in the last quarter. Cerebellum GP LLC acquired a new stake in shares of LivaNova in the third quarter valued at $128,000. Finally, Dupont Capital Management Corp acquired a new stake in shares of LivaNova in the third quarter valued at $211,000. Institutional investors and hedge funds own 87.77% of the company’s stock.
Several analysts have recently issued reports on the company. Stifel Nicolaus increased their price objective on LivaNova from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, November 25th. BidaskClub cut LivaNova from a “hold” rating to a “sell” rating in a research note on Tuesday, December 24th. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of LivaNova in a research note on Wednesday, November 20th. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research cut LivaNova from a “hold” rating to a “sell” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. LivaNova has a consensus rating of “Hold” and a consensus target price of $96.00.
In other LivaNova news, Director Daniel Jeffrey Moore sold 3,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $80.00, for a total transaction of $240,000.00. Following the transaction, the director now owns 28,352 shares of the company’s stock, valued at $2,268,160. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $83.71, for a total value of $83,710.00. Following the transaction, the chief executive officer now directly owns 66,016 shares in the company, valued at approximately $5,526,199.36. The disclosure for this sale can be found here. Insiders sold 6,000 shares of company stock worth $473,090 in the last three months. 0.41% of the stock is currently owned by corporate insiders.
NASDAQ:LIVN traded up $0.50 during trading hours on Friday, hitting $75.66. The company’s stock had a trading volume of 2,808 shares, compared to its average volume of 314,373. The stock has a market capitalization of $3.60 billion, a P/E ratio of 23.87, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The stock has a fifty day moving average of $76.78 and a 200-day moving average of $76.12. The company has a current ratio of 1.17, a quick ratio of 0.81 and a debt-to-equity ratio of 0.21. LivaNova PLC has a 52-week low of $64.80 and a 52-week high of $102.43.
LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, October 30th. The company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.75 by $0.09. The firm had revenue of $268.60 million for the quarter, compared to analyst estimates of $273.41 million. LivaNova had a positive return on equity of 9.44% and a negative net margin of 20.35%. LivaNova’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 earnings per share. On average, sell-side analysts forecast that LivaNova PLC will post 2.69 earnings per share for the current year.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: What is a back-end load?
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.